Trial Profile
Study to evaluate the Hepatic safety of Febuxostat Compared to Allopurinol in Gout Patients with Fatty Liver Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Nov 2018
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary) ; Allopurinol
- Indications Gout
- Focus Adverse reactions
- 19 Nov 2018 New trial record
- 15 Nov 2018 Results (n=32) assessing the efficacy of febuxostat in gout and fatty liver disease patients, published in The Journal of Rheumatology.
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting